This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Jump to section
Related Articles
Cited By...
- Phase I study of the 177Lu-DOTA0-Tyr3-Octreotate (lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lung
- The SNM Practice Guideline for Somatostatin Receptor Scintigraphy 2.0
- The role of somatostatin and dopamine D2 receptors in endocrine tumors
- Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors
- Added value of gastrin receptor scintigraphy in comparison to somatostatin receptor scintigraphy in patients with carcinoids and other neuroendocrine tumours
- Effects of Therapy with [177Lu-DOTA0, Tyr3]Octreotate in Patients with Paraganglioma, Meningioma, Small Cell Lung Carcinoma, and Melanoma
- Radiation Therapy of Small Cell Lung Cancer with 177Lu-DOTA-Tyr3-Octreotate in an Animal Model
- Somatostatin Receptor Scintigraphy in Liver Metastasis Detection from Gastroenteropancreatic Neuroendocrine Tumors
- Molecular Biologic and Scintigraphic Analyses of Somatostatin Receptor-Negative Meningiomas
- Peptide Receptor Imaging and Therapy